PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsZurex Pharma
Zurex Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
ZuragardFenofibrate2019-04-262024-2033
Hypercholesterolemia
,
Coronary artery disease
,
Dyslipidemias
,
Hypertriglyceridemia
,
Hyperlipoproteinemias
,
Periodontal diseases
,
Infectious skin diseases
,
Gram-negative bacterial infections
,
Oral candidiasis
,
Gram-positive bacterial infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fenofibrate
preoperative care
,
infections
,
communicable diseases
Bevifimod
peripheral arterial disease
,
intermittent claudication
,
peripheral vascular diseases
,
neoplasms
,
hypophosphatemic rickets
,
hemophilia b
,
pseudoxanthoma elasticum
,
genetic therapy
,
mucopolysaccharidosis iv
,
hemophilia a
,
lysosomal storage diseases
,
hematologic diseases
,
blood coagulation disorders
,
hemostatic disorders
,
inborn genetic diseases
,
hemorrhagic disorders
,
inherited blood coagulation disorders
,
coagulation protein disorders
,
phenylketonurias
Riboprine
infections
,
communicable diseases
Crystalloid
merkel cell carcinoma
Zuraprep
surgical wound infection
Chloraprep
surgical wound infection
Corsodyl
healthy volunteers/patients
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use